Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date

• Main Authors: Sawalha Y, Bond DA, Alinari L
• Format: Article
• Language: English
• Published: Dove Medical Press 2020-07-01
• Series: OncoTargets and Therapy
• Subjects: btk; zanubrutinib; ibrutinib; acalabrutinib
• Online Access: https://www.dovepress.com/evaluating-the-therapeutic-potential-of-zanubrutinib-in-the-treatment--peer-reviewed-article-OTT

Yazeed Sawalha, David A Bond, Lapo Alinari Department of Internal Medicine, Division of Hematology, Arthur G. James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USACorrespondence: Yazeed SawalhaDepartment of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital, A350B Starling-Loving Hall, 320 W. 10th Ave., Columbus, OH 43210, USATel [phone]Fax [phone]Email [e-mail]: Mantle cell lymphoma (MCL) is an uncommon B-cell non-Hodgkin lymphoma characterized by an aggressive clinical course in the majority of patients. Despite recent improvements in outcomes, MCL remains incurable and a major therapeutic challenge. BTK inhibitors are the preferred treatment option for patients with relapsed/refractory MCL, including those unfit for chemotherapy or those with chemoresistant disease. In addition to ibrutinib and acalabrutinib, the FDA recently approved zanubrutinib for the treatment of patients with relapsed/refractory MCL based on the results of two Phase 2 clinical trials showing overall response rates of 85– 87% with complete responses in 30– 77% of patients. Compared with ibrutinib, zanubrutinib is more selective for BTK and has less off-target inhibition, which is thought to limit certain toxicities although direct comparative data are still lacking. This review article summarizes data from clinical trials of currently FDA-approved BTK inhibitors in MCL with a focus on zanubrutinib.Keywords: BTK, zanubrutinib, ibrutinib, acalabrutinib